text_1: The most prevalent adverse events to Semaglutide are cardiovascular.
text_2: Objectives To compare the effects of oral semaglutide with placebo (primary) and open-label subcutaneous semaglutide (secondary) on glycemic control in patients with type 2 diabetes.